What M&A slowdown? Buyers circle GreenLight Biosciences, Egitis Therapeutics

While biotech M&A may have cooled down over the past year, no one has told GreenLight Biosciences or Egitis Therapeutics, which are both mulling takeover offers.

RNA-focused GreenLight announced yesterday that it has received an offer from VC firm Fall Line Capital’s Fall Line Endurance Fund to acquire all outstanding stock of the biotech for 60 cents per share.